Protagonist Therapeutics Receives $275 Million in Milestone Payments Triggered by Mimrylo FDA Approval
Protagonist Therapeutics (NASDAQ: PTGX) disclosed Friday August 28, 2026 that the Mimrylo FDA approval triggers $275 million in payments from Takeda, consisting of a $200 million opt-out fee (representing Protagonist's decision not to co-commercialize) and a separate $75 million approval milestone. The company retains additional undisclosed milestones and tiered royalties on rusfertide sales under the January 2024 worldwide license and collaboration agreement. Protagonist's platform-derived pipeline extends beyond rusfertide to include icotrokinra (an oral IL-23 receptor antagonist peptide licensed to Janssen, with a broad autoimmune-disease Phase 3 program) plus additional preclinical peptide programs across metabolic, inflammatory, and hematologic indications. The company's stock is expected to be one of the notable peptide-focused public-market performers of 2026 as rusfertide commercial ramp and icotrokinra Phase 3 readouts advance.